Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7™ CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. The company was founded in 2015 and is headquartered in Boulder, Colorado.
Discover the best career opportunities with the best company cultures for you.
Connect your business to thousands of engaged professionals in your city and beyond.